Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | BRUIN study cohort update: pirtobrutinib for patients with MCL

Michael Wang • 6 Sep 2023
SOHO 2023
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma BTK inhibitors Pirtobrutinib
BRUIN

Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the updated results from the Phase I/II BRUIN study (NCT03740529) investigating the oral agent pirtobrutinib for relapsed/refractory mantle cell lymphoma (R/R MCL), highlighting the response rates observed in both BTK inhibitor-naïve and -exposed patients. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Wang

3:37
SYMPATICO: ibrutinib combined with venetoclax in patients with R/R MCL
Michael Wang • 11 Dec 2023
1:57
Improvements and remaining challenges in treating R/R MCL after failure of BTK inhibitors
Michael Wang • 6 Sep 2023
2:27
Lisocabtagene maraleucel for R/R MCL: TRANSCEND-NHL-001 update
Michael Wang • 6 Sep 2023
0:51
The role of transplantation for patients with MCL in the era of CAR-T therapy
Michael Wang • 6 Sep 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals